• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析概念与应用的新方向。

New directions in peritoneal dialysis concepts and applications.

作者信息

Nolph K D, Miller F, Rubin J, Popovich R

出版信息

Kidney Int Suppl. 1980 Sep;10:S111-6.

PMID:6934332
Abstract

A limited number of peritoneal capillaries involved in solute exchange during peritoneal dialysis and inaccessible stagnant fluid films within the peritoneal interstitium may account for most resistance to solute transport during peritoneal dialysis. The control of small solute concentrations in blood by intermittent peritoneal dialysis will probably always require 30 to 40 hr/week of treatment even with the most rapid cycling devices. Increased understanding of factors that effect the microcirculation of the peritoneum may allow manipulation of protein losses and optimization of the long-term health of the peritoneum but will probably have little impact on the efficiency of small solute transport. CAPD accepts peritoneal dialysis as a low-efficiency system in terms of small solute clearances and yet yields similar weekly clearances to hemodialysis for small solutes by utilizing continuous dialysis. Large solute clearances with CAPD markedly exceed weekly clearances with hemodialysis.

摘要

腹膜透析过程中参与溶质交换的腹膜毛细血管数量有限,以及腹膜间质内难以触及的停滞液膜,可能是腹膜透析过程中溶质转运阻力的主要原因。即使使用最快的循环装置,通过间歇性腹膜透析控制血液中小溶质浓度可能仍需要每周治疗30至40小时。对影响腹膜微循环因素的进一步了解,可能有助于控制蛋白质流失并优化腹膜的长期健康状况,但可能对小溶质转运效率影响不大。就小溶质清除率而言,持续性非卧床腹膜透析(CAPD)认为腹膜透析是一种低效系统,但通过持续透析,其小溶质每周清除率与血液透析相似。CAPD的大溶质清除率明显超过血液透析的每周清除率。

相似文献

1
New directions in peritoneal dialysis concepts and applications.腹膜透析概念与应用的新方向。
Kidney Int Suppl. 1980 Sep;10:S111-6.
2
Peritoneal dialysis: physiology, current applications and future directions.腹膜透析:生理学、当前应用及未来方向。
Proc Eur Dial Transplant Assoc. 1979;16:277-85.
3
Peritoneal clearances.
J Lab Clin Med. 1979 Oct;94(4):519-25.
4
What we have learned about uremia from peritoneal dialysis.我们从腹膜透析中学到的关于尿毒症的知识。
ASAIO J. 1992 Oct-Dec;38(4):745-50.
5
Time dependence of solute removal during a single exchange.单次交换过程中溶质清除的时间依赖性。
Adv Perit Dial. 1997;13:23-8.
6
In vitro simulations of peritoneal dialysis. A technique for demonstrating limitations on solute clearances due to stagnant fluid films and poor mixing.
J Lab Clin Med. 1980 Jul;96(1):148-57.
7
How does peritoneal dialysis remove small and large molecular weight solutes? Transport pathways: fact and myth.腹膜透析是如何清除小分子和大分子溶质的?转运途径:事实与误解。
Adv Perit Dial. 1990;6:13-8.
8
Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD.持续性非卧床腹膜透析(CAPD)开始时糖尿病患者与非糖尿病患者之间液体和溶质转运的差异。
Adv Perit Dial. 1997;13:29-32.
9
The peritoneal microcirculation in peritoneal dialysis.腹膜透析中的腹膜微循环
Microcirculation. 2001 Oct;8(5):303-20. doi: 10.1038/sj/mn/7800106.
10
Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide?氨基酸基透析液对稳定期持续性非卧床腹膜透析患者腹膜血流及通透性的影响:一氧化氮的潜在作用?
Clin Nephrol. 1996 May;45(5):295-302.

引用本文的文献

1
Intercellular localization of occludins and ZO-1 as a solute transport barrier of the mesothelial monolayer.作为间皮单层溶质转运屏障的闭合蛋白和紧密连接蛋白1的细胞间定位
J Artif Organs. 2006;9(4):241-50. doi: 10.1007/s10047-006-0350-3. Epub 2006 Dec 21.
2
Comparison of plasma and peritoneal concentrations of various categories of MRI blood pool agents in a murine experimental pharmacokinetic model.在小鼠实验药代动力学模型中各类MRI血池造影剂的血浆和腹膜浓度比较。
MAGMA. 2001 May;12(2-3):82-7. doi: 10.1007/BF02668086.
3
Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.
接受腹膜透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1985 Sep-Oct;10(5):404-25. doi: 10.2165/00003088-198510050-00003.
4
Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.复方新诺明(磺胺甲恶唑加甲氧苄啶)腹膜屏障转运的药代动力学。
Clin Pharmacokinet. 1989 May;16(5):317-25. doi: 10.2165/00003088-198916050-00004.